Video above: CDC says COVID-19 patients were twice as likely to be restaurant patronsScientists at the University of Pittsburgh School of Medicine say they have identified a small molecule that neutralizes SARS-CoV-2, the coronavirus that causes COVID-19.They say it’s a small piece of an antibody, and that it has been used to construct a drug that might be used to treat or even prevent COVID-19.Pitt scientists worked with colleagues from several other universities and published their findings in the journal Cell on Monday. They say the drug — Ab8 — prevents and treats coronavirus infection in mice and hamsters, and there are good indications that it could eventually be used to treat people.”Ab8 not only has potential as therapy for COVID-19, but it also could be used to keep people from getting SARS-CoV-2 infections,” said Dr. John Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC. “Antibodies of larger size have worked against other infectious diseases and have been well tolerated, giving us hope that it could be an effective treatment for patients with COVID-19 and for protection of those who have never had the infection and are not immune.”A UPMC-backed company is licensing Ab8 for development around the world. A timeline wasn’t immediately clear.Mellors and other UPMC and Pitt leaders were expected to discuss more details at a news conference on Tuesday afternoon.

Video above: CDC says COVID-19 patients were twice as likely to be restaurant patrons

Scientists at the University of Pittsburgh School of Medicine say they have identified a small molecule that neutralizes SARS-CoV-2, the coronavirus that causes COVID-19.

Advertisement

They say it’s a small piece of an antibody, and that it has been used to construct a drug that might be used to treat or even prevent COVID-19.

Pitt scientists worked with colleagues from several other universities and published their findings in the journal Cell on Monday. They say the drug — Ab8 — prevents and treats coronavirus infection in mice and hamsters, and there are good indications that it could eventually be used to treat people.

“Ab8 not only has potential as therapy for COVID-19, but it also could be used to keep people from getting SARS-CoV-2 infections,” said Dr. John Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC. “Antibodies of larger size have worked against other infectious diseases and have been well tolerated, giving us hope that it could be an effective treatment for patients with COVID-19 and for protection of those who have never had the infection and are not immune.”

A UPMC-backed company is licensing Ab8 for development around the world. A timeline wasn’t immediately clear.

Mellors and other UPMC and Pitt leaders were expected to discuss more details at a news conference on Tuesday afternoon.

Source